News
May 12, 2026
Exciva appoints distinguished biopharma leader Mark Altmeyer as chairman of the board
Strategic appointment underscores Exciva’s ambition to advance Deraphan, its lead product to treat agitation in Alzheimer’s patients, through late-stage development and global expansion.
April 28, 2026
Exciva doses first patient in Phase 2/3 trial of Deraphan for agitation in Alzheimer’s disease and extends Series B round.
SERENADA trial to run at up to 60 sites across US, UK, Canada and Europe, targeting 300 patients.
Exciva brings Series B round to €53M, with Dolby Ventures joining investor pool, and strengthens management with appointment of seasoned COO.
January 20, 2026
Exciva GmbH today announces the closing of a €51 million ($59m) Series B financing round. Gimv and EQT Life Sciences co-led the round. Additional participants included new investors Fountain Healthcare Partners, LifeArc Ventures, Carma Fund and Modi Ventures, as well as existing investors Andera Partners and LBBW.
Download Press Release >>>
February 12, 2025
Fiona Hattey joined the Exciva team as Head of Clinical Operations. She has over thirty years of experience in operationalizing clinical trials.
November 4, 2024
Our lead program, EXV-802 for the treatment of agitation in dementia associated with Alzheimer’s disease, received a Fast Track designation from the US FDA
April 1, 2024
Dr Hans Moebius, co-founder of Exciva, re-joined the team as a Chief Medical Officer bringing with him over thirty years of leadership in Neurology and Psychiatry drug development and translational medicine
June 1, 2023
Francisco Orellana, a seasoned professional who has worked in the biotech sector for over twenty years, joined Exciva as Chief Financial Officer
October 25, 2022
The US PTO granted a patent to Exciva for its invention of innovative composition of matter with various therapeutic uses in neuropsychiatry
October 11, 2022
Exciva successfully completed Phase I study of its proprietary EXV-802 combination of dextromethorphan and a 5-HT2A/2C receptor inverse agonist
October 26, 2021
Exciva raises €9 million in Series A round led by Andera Partners (full press release)